A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

Stopped early · Phase 1

Conditions studied: Renal Insufficiency, Pharmacokinetics

In brief

1. To investigate the effect of kidney function on the elimination of a single dose of PD 0332334 from the body. 2. To investigate the safety and tolerability of a single dose of PD 0332334 in patients with impaired kidney function.

Key facts

Study ID

NCT00721422

Run by

Pfizer

People needed

16

Starts

2008-08-01

Expected to finish

2009-02-01

Last updated by the study team

2010-02-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy volunteers OR subjects with kidney impairment

You may not qualify if…

• Receiving hemodialysis
• clinically significant or unstable medical disease other than kidney disease

Where it is running

• Pfizer Investigational Site — Cypress, California, United States
• Pfizer Investigational Site — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.